Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Risks Of Using Celebrity Endorsers Shown In Woods' Loss Of Marketing Deals

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

The decision by Procter & Gamble's Gillette personal care products to curtail its use of golf superstar Tiger Woods in promotions reflects consumer product firms' tendencies when celebrity endorsers incur credibility problems

You may also be interested in...



People In Brief

GSK Consumer adds J&J veteran

People In Brief

GSK Consumer adds J&J veteran

P&G Eyes Expanded Gillette Skin Care And Hair Care Offerings

Procter & Gamble will focus on growing Gillette's brand equity and product offerings in the midterm, P&G CFO Clayt Daley told analysts during an Oct. 3 conference call. P&G's $57 bil. acquisition of Gillette closed Oct. 1, one day after receiving FTC approval

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS103690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By